Main Barriers to States Expanding Medicaid
Even though Medicaid coverage varies greatly from state to state, now under the Affordable Care Act’s option to expand the program, there are ways the public and private sectors can cooperate to provide care, Leah Binder said. Maternity care is a good example since Medicaid pays for half of the births in the United States and the other half are purchasers. But both sides are concerned about the rise in the rate of caesarean sections across the country.
“If we start aligning and working together on these issues, I think there can be some real progress,” she said. “And that’s regardless of the expansion. That can happen in any state.”
Meanwhile, Austin Frakt, PhD wondered how much the hesitation to expand Medicaid, which mostly occurred in red states, is a result of politicians waiting for a change in the administration. Matt Salo admitted that the top reason why states haven’t expanded the program is political, and pushback tends to come from the state house of representatives.
The second reason states haven’t expanded Medicaid is financial, and third is ideological. States are trying to figure out how to structure Medicaid expansion so that it makes sense for their residents. That’s why some states, such as Arkansas, Indiana, Iowa, and Michigan, have gone a different route with their expansion plans.
“How do you create a program that meets the ideological needs of people who think differently about healthcare?” Salo asked. “How do you engage the consumer in a different way than Medicaid traditionally has?”
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More